A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

A new imaging technique could mean patients with aggressive brain tumours benefit from cutting edge immunotherapy treatments, ...

This course provides practical and theoretical education for the support of a modern radiotherapy physics service within radiotherapy. It is aimed primarily at recently qualified radiotherapy ...

Help women with ovarian and breast cancer live longer and better lives by supporting the Institute of Cancer Research. Donate ...

Applications are now open for our 2024/2025 PhD studentships. Below you will find a link to further information about our application process, our application portal and mailing list, should you wish ...

Professor Clare Isacke aims to identify the processes by which tumour cells recruit non-cancerous cells during metastasis. She has held several senior positions at the ICR, including acting as Interim ...

Professor Richard Houlston is Head of the Division of Genetics and Epidemiology. His research focuses on the identification and characterisation of genetic susceptibility to cancer. Group: Myeloma ...

The Institute of Cancer Research, London, has been driving scientific discoveries on cancer and its treatment for more than 100 years. We are internationally renowned for our work into cancer genetics ...

Scientists at the ICR were responsible for two landmark studies that could ultimately change how we think about cancer and its treatment. In a phase I trial, a cancer drug discovered by scientists now ...

A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial. Researchers found that RP2 – a modified version of the herpes ...

Professor Nicholas Turner is an Academic Consultant Medical Oncologist who specialises in breast cancer treatment. He is a Group Leader in the Breast Cancer Now Toby Robins Research Centre and Chief ...

The FAST trial aims to test 5 fractions of 5.7 Gy and 6.0 Gy against 25 fractions of 2.0 Gy in terms of late normal tissue effects and tumour control in women prescribed whole breast radiotherapy (no ...